Apoptosis inhibitor prevented the decrease of IIL ESP-induced TJs expression and alleviated barrier disruption of Caco-2 monolayer. by Qi Qi Lu (17721401)

“…<p><b>A:</b> Apoptosis inhibitor Z-VAD-FMK pretreatment increased the IIL ESP-decreased TEER. …”

eGFR values and mean eGFR change after the use of dulaglutide. by Sungmin Kim (628527)

Subjects:

Preoperative and postoperative questionnaire scores of groups A, B, C, D, E, F, and G. by Régis Cohen (11419436)

Subjects:

PI+ CD3+ T cells decrease at day 14 after IR while PI+ CD3- cells decrease at all time points. by Jordan A. Gunning (18143970)

Changes in work exposure as a function of relative time and mean exposure. by Danuta Roman-Liu (8532645)

Graphs showing the mean temperature increase at the positions with the highest mean temperature increase for the MIPS (A) and MONO (B) systems and three drilling protocols (DP1, DP... by Marsel Ganeyev (21453399)

Naringenin decreases total cell viability. by Lauren A. Eanes (20995499)

Preoperative and postoperative scores for the different dimensions of BAROS scores in groups A, B, C D, E, F, and G. by Régis Cohen (11419436)

Subjects:

(Related to Fig 5B and 5C). Comparison of mean percentages of transfected cells with SGs calculated from three biological triplicates, showing the decrease in % as compared to wt N or the mutant N1a+N2b N. by Chiara Aloise (8374950)

Annual mean O₃ and PM_2.5 concentration in 2014 for postal codes in the study. by John Brandt (6880463)

Effects of FE and RUD wrist postures on the mean carpal tunnel depth within each quartile. by Drew A. Anderson (14197446)

Subjects:

Effects of FE and RUD wrist postures on the mean carpal tunnel width within each quartile. by Drew A. Anderson (14197446)

Subjects:

Effects of FE and RUD wrist postures on the mean cross-sectional area within each quartile. by Drew A. Anderson (14197446)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects: